Buckley Wealth Management LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Buckley Wealth Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 7.0% during the third quarter, Holdings Channel.com reports. The firm owned 40,600 shares of the company’s stock after selling 3,051 shares during the quarter. Johnson & Johnson accounts for 2.6% of Buckley Wealth Management LLC’s investment portfolio, making the stock its 13th largest holding. Buckley Wealth Management LLC’s holdings in Johnson & Johnson were worth $5,253,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Johnson & Johnson by 0.7% in the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock valued at $31,360,143,000 after acquiring an additional 1,627,370 shares during the period. Phocas Financial Corp. increased its position in shares of Johnson & Johnson by 999,928.6% in the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $174,342,000 after acquiring an additional 125,161,066 shares during the period. Northern Trust Corp increased its position in shares of Johnson & Johnson by 0.9% in the second quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock valued at $4,910,381,000 after acquiring an additional 313,073 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Johnson & Johnson by 11.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock valued at $2,895,870,000 after acquiring an additional 2,204,757 shares during the period. Finally, Morgan Stanley increased its position in shares of Johnson & Johnson by 0.6% in the second quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock valued at $2,784,913,000 after acquiring an additional 122,033 shares during the period. Institutional investors own 72.01% of the company’s stock.

JNJ has been the topic of a number of analyst reports. Bank of America restated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Credit Suisse Group set a $156.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Raymond James decreased their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Finally, Sanford C. Bernstein upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research report on Friday. Five investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $151.00.

Shares of JNJ opened at $131.33 on Friday. The firm’s 50-day moving average price is $129.92 and its 200-day moving average price is $134.97. The firm has a market capitalization of $347.95 billion, a price-to-earnings ratio of 16.06, a PEG ratio of 2.22 and a beta of 0.69. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.42 by $0.16. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.10 EPS. On average, research analysts forecast that Johnson & Johnson will post 8.59 EPS for the current fiscal year.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: What is operating income?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.